About Company
Founded in 2015 and headquartered in North Melbourne, Victoria, Australia, Telix Pharmaceuticals specializes in creating innovative products that utilize molecularly targeted radiation for the treatment and diagnosis of various cancers. The company is publicly listed on the Australian Securities Exchan
Key Areas of Focus
- Radiopharmaceuticals: Developing both diagnostic and therapeutic products aimed at treating cancers such as prostate, renal, brain, and hematologic cancers.
- Theranostics: Combining therapy and diagnostics to improve patient outcomes through personalized medicine.
- Global Operations: Telix operates in multiple countries, including Australia, Austria, Belgium, China, the United Kingdom, and the United States.
The company has an extensive pipeline of products in various stages of clinical development, emphasizing its commitment to addressing unmet medical needs in oncology.ge (ASX) under the code TLX.